COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis

COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis

Nils Venhoff, Markus A. Schramm, Dirk Wagner, Jens Thiel, Daniela Huzly, Nils Craig-Mueller, Marcus Panning, Hartmut Hengel, Winfried V. Kern, Reinhard E. Voll

Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).

2020

covid-19, SARS-CoV-2, immunosuppression, vasculitis, EGPA, eosinophilic granulomatosis with polyangiitis

10.3389/fimmu.2020.02086

Epidemiology and Health

Korean Society of Epidemiology

Immunologic diseases. Allergy